Six months into 2023, one thing is clear — the pharma industry is halfway through a landmark year. On the M&A front, the industry has already seen a flurry of deals, from Merck’s $11 billion buy of Prometheus Biosciences, to Pfizer’s $43 billion Seagen acquisition and Sanofi’s $3 billion purchase of Prevention Bio.

As the 2024 presidential campaign heats up, the industry’s own Vivek Ramaswamy, founder of Roivant Sciences, could take the stage at the first Republican primary debate, slated for late August.

Here at PharmaVoice, we’re tracking these and other major events impacting the life sciences. Take a look at the some of our most-read articles of the year so far.